| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia |
|
Medicine details |
|
| Medicine name | gilteritinib (Xospata®) |
| Formulation | 40 mg film-coated tablet |
| Reference number | 3113 |
| Indication | Monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia with a FLT3 mutation |
| Company | Astellas Pharma Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 10/10/2019 |
| NICE guidance | TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia |
| Commercial arrangement | PAS |